News

BioSpace1d
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial
Govorestat failed to meet its primary endpoint in a Phase II/III trial for a rare form of Charcot-Marie-Tooth disease, a few ...
Fierce Biotech1d
Applied's rare disease drug suffers another phase 3 failure months after FDA rejection
Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...
Applied Therapeutics Reports First Quarter 2025 Financial Results
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for ...
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Detailed price information for Applied Therapeutics Inc (APLT-Q) from The Globe and Mail including charting and trades.
American Association of Individual Investors14d
Why Applied Therapeutics, Inc.’s (APLT) Stock Is Down 6.65%
Applied Therapeutics, Inc.’s APLT share price has dipped by 6.65%, which has investors questioning if this is right time to ...
Nature3y
Galactosemia, a Single Gene Disorder With Epigenetic Consequences
Galactosemia (GAL) (McKusick 230400) caused by deficiency of galactose-1-phosphate uridyltransferase (GALT: EC 2.7.712) is associated with an impaired ability to metabolize galactose, derived from ...